Conigen News and Events
DivcoWest and BVS' Biotech Summer BBQ Event at Cambridge Crossing
Date: Wednesday, July 30, 2025
Event Time: 11:00 AM – 1:30 PM
Location: 222 Jacobs St, Cambridge, MA 02141
Live Webinar: Uncovering New Tools to Analyze Cytokine-Receptor Interactions
How Conigen Bioscience Used Nicoya's AltoTM DIgital SPR to Characterize Novel Dimeric Receptors
Tuesday, August 5, 2025
11 AM EST / 8 AM PST
Overview
Understanding cytokine-receptor interactions is critical for advancing immunology research and therapeutic development, but capturing these interactions in a native-like state can be challenging.
In this webinar, Conigen Bioscience’s Assay Development Scientist, Dr. Alyssa Ball will share how they leveraged Nicoya’s Alto digital surface plasmon resonance (SPR) system to characterize the binding kinetics of several homo- and heterodimeric cytokine receptors, including human Type II interferon γ receptor 1 (IFNγR1) and human Type I interferon α receptor (IFNαR).
Topics covered in this webinar:
How Conigen Bioscience’s innovative soluble protein dimers enhance ligand binding sensitivity and potency of cytokine receptor proteins
Why SPR was critical for revealing nuanced differences in binding potency
How Alto digital SPR enables rapid, high-quality kinetic data for complex receptor-ligand systems
How real-time, label-free kinetic analysis combined with structural and stability characterization can accelerate the selection of functionally relevant and stable therapeutic candidates
Whether you’re working in basic immunology or drug discovery, this webinar will showcase how these innovative soluble cis-dimer proteins can significantly enhance binding potency and enable more accurate characterization of complex protein interactions.
Conigen Bioscience is Exhibiting at Discovery on Target
23rd Annual Discovery on Target
September 23-25
Sheraton Hotel, Boston
Booth #509
Scientist.com Vendor Discovery Day - Boston 2025
Date: Tuesday, october 21, 2025
Event Time: 11:00 AM – 2:00 PM
Location: Catalyst Restaurant, Cambridge, MA 02139
What’s New at Conigen: Expanded Custom Recombinant Protein and Antibody Services
As part of our commitment to supporting discovery with high-quality, native-like proteins, Conigen has expanded its custom protein expression and antibody solutions. These services are built on our proprietary technology platforms and decades of applied experience in protein expression, antibody generation, and functional validation.
We offer a modular, milestone-driven workflow with standardized quality control checkpoints—allowing our clients to scale up with confidence and receive project-ready functional recombinant proteins or high purity and specificity recombinant or monoclonal antibodies .
Expanded Custom Recombinant Protein and Antibody Development for Drug Discovery:
Custom Conformational Protein Expression
- Design and expression of soluble or full-length membrane proteins
- Proprietary cis-dimer motif with stabilization domains
- Optimized for native-like structure and functional bioactivity
- Deliverable: Validated protein (milligram quantities) and project data report
- Learn about single-pass ectodomain soluble proteins: CD3 epsilon/delta, IL-2Rb/g
- View multi-pass membrane associated proteins: Claudin 6, Claudin 9, CXCR4
Recombinant Antibody Expression in HEK293 Cells
- Production of target-specific antibody plasmids (heavy and light chains)
- Expression yields suitable for screening and characterization
- Deliverable: Milligram quantities of purified antibody and data report
Mouse Monoclonal Antibody (mAb) Development
- Custom immunization strategies (membrane targets, weak immunogens)
- High-affinity mAbs generated via hybridoma technology
- Deliverable: Clonal hybridoma lines and 1 mg purified mAb and data report
Why It Matters
Nature doesn’t compromise on structure. Neither do we.
Conigen’s recombinant protein platforms solve persistent bottlenecks in discovery by recreating the structural context that proteins require for biological activity. Whether you’re screening therapeutic antibodies, testing drug-receptor interactions, or designing immunogens, functionally validated, native-like proteins reduce false positives and speed up validation.
- Bioactivity confirmed through ELISA, flow cytometry, or ligand-binding assays
- Broader screening windows than monomers
- Reduced need for re-screening and troubleshooting
From Concept to Confidence
Every custom project at Conigen is guided by a foundational belief: the closer we mimic nature, the more reliable the research outcome.
Whether you’re working on antibody discovery, immune profiling, or therapeutic target validation, our platforms are designed to increase efficiency without compromising structural integrity. We don’t just deliver materials — we deliver confidence in the form of bioactive, native-like molecules that perform as expected.
What’s New at Conigen: Conformational Recombinant Proteins with New Data, New Insights — See Us at AAI 2025 and PEGS
In addition to expanding our portfolio of recombinant proteins that mimic nature, Conigen scientists will be presenting new data at two leading scientific conferences this May, AAI 2025 (booth #539) in Honolulu and PEGS (booth #511) in Boston.
Our posters focus on improving binding affinity, epitope accessibility, and recombinant protein formats for difficult-to-express targets like GPCRs, cytokine receptors, and immune co-stimulatory molecules.
AAI 2025
| Chemokine receptors CXCR4 or CXCR5 displayed on nanoparticles are bioactive and able to bind its relevant ligand CXCL12 or CXCL13 Poster #406 Focus: Functional validation of full-length GPCRs in VLP format |
| Engineered novel cytokine receptors IFNγR1, IL10Rα and IFNαR1/2 cis-dimers significantly enhance the binding of the relevant cytokines IFNγ, IL-10 and IFNα Poster #411 Focus: Improved bioactivity for cytokine binding and screening |
| Engineered novel CD4 cis-dimer protein significantly enhances the binding of HIV-1 envelope glycoproteins Poster #2257 Focus: Application in HIV entry models and antibody screening |
| Engineered Nectin-4 and CD155 novel cis-dimer proteins significantly enhance the binding of their receptor TIGIT Poster #2013 Focus: Recombinant tumor associated antigen and checkpoint receptor with enhanced bioactivity |
2025 PEGS Boston Summit
Recombinant G-Protein Coupled Chemokine Receptors CXCR4 and CXCR5 on Nanoparticles are Bioactive, Binding to the Chemokine Ligands |
Engineered Immune Checkpoint CD28 and CTLA-4 Homodimer Proteins Demonstrate Potent Binding Affinities to Their Ligand CD80 |
Engineered Novel CD155 and Nectin-4 Homodimer Proteins Dramatically Enhance Binding Affinities to Their Receptor TIGIT Compared to Respective Monomers |
Novel Soluble Cytokine Receptors IFNγR1 Homodimer and IFNαR1/R2 Heterodimer Enhance Binding to Type II and Type I Interferons Compared to Monomers |
Why It Matters:
Proteins don’t function in isolation — they work within complex biological environments. Our approach focuses on: protein structure isn’t just a feature, it’s the function. These poster presentations provide new data demonstrating how preserving these native conformations can lead to:
- Improved binding potency
- Broader screening windows
- Better tool-molecules for translational immunology
Explore Our Approach: Nature did it first. We make it available.
Conigen recombinant proteins are available as catalog items or as starting points for custom development. Every protein is developed with one goal in mind: creating native-like research tools that move your science forward with greater confidence. View all recombinant proteins here